MeSH term
Frequency | Condition_Probility | Female | 238 | 0.0 |
Humans | 726 | 0.0 |
Pregnancy | 6 | 0.0 |
Review Literature | 2 | 1.0 |
Acute Disease | 7 | 0.0 |
Adult | 214 | 0.0 |
Comparative Study | 77 | 0.0 |
Aged | 98 | 0.0 |
Cardiac Output, Low/*mortality | 2 | 3.0 |
Coronary Arteriosclerosis/mortality | 2 | 3.0 |
Risk | 2 | 0.0 |
Surgical Procedures, Elective/*mortality | 2 | 3.0 |
Time Factors | 18 | 0.0 |
Animals | 61 | 0.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Gene Expression | 11 | 0.0 |
Adolescent | 62 | 0.0 |
English Abstract | 35 | 0.0 |
Middle Aged | 171 | 0.0 |
Retrospective Studies | 12 | 0.0 |
Biopsy | 27 | 1.0 |
Infant | 41 | 0.0 |
Male | 224 | 0.0 |
Prednisone/therapeutic use | 4 | 3.0 |
Skin/pathology | 12 | 4.0 |
Antigens, CD/analysis | 70 | 4.0 |
Cell Culture Techniques/methods | 7 | 3.0 |
Cell Differentiation/drug effects | 33 | 3.0 |
Dendritic Cells/cytology/*drug effects | 2 | 100.0 |
Immunophenotyping | 112 | 3.0 |
Immunosuppressive Agents/*pharmacology | 6 | 2.0 |
Monocytes/cytology/drug effects | 3 | 8.0 |
Research Support, Non-U.S. Gov't | 390 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Chronic Disease | 11 | 0.0 |
Immunohistochemistry | 146 | 1.0 |
Cell Line | 25 | 0.0 |
Dendritic Cells/*immunology | 24 | 9.0 |
T-Lymphocytes, Cytotoxic/*immunology | 5 | 0.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 20 | 5.0 |
Clone Cells | 5 | 0.0 |
DNA/genetics | 3 | 0.0 |
Dosage Compensation (Genetics) | 2 | 1.0 |
Microscopy, Electron | 50 | 2.0 |
Polymerase Chain Reaction | 16 | 0.0 |
Receptors, Androgen/genetics | 2 | 3.0 |
S100 Proteins/analysis | 22 | 11.0 |
Adjuvants, Immunologic/physiology | 2 | 4.0 |
Antigens, CD1/biosynthesis | 9 | 56.0 |
CD40 Ligand/physiology | 2 | 15.0 |
Cell Differentiation/immunology | 26 | 8.0 |
Cells, Cultured | 120 | 0.0 |
Coculture Techniques | 14 | 2.0 |
Dendritic Cells/cytology/*immunology/metabolism | 2 | 15.0 |
Dose-Response Relationship, Immunologic | 3 | 0.0 |
Down-Regulation/immunology | 4 | 4.0 |
*Drosophila Proteins | 2 | 0.0 |
Drug Combinations | 2 | 0.0 |
Endocytosis/immunology | 2 | 9.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 39 | 9.0 |
Interferon Type II/biosynthesis | 3 | 0.0 |
Interleukin-10/biosynthesis | 4 | 3.0 |
Interleukin-3/*pharmacology | 2 | 1.0 |
Leukocyte Count | 7 | 0.0 |
Lymphocyte Culture Test, Mixed | 47 | 7.0 |
Membrane Glycoproteins/biosynthesis/genetics | 2 | 4.0 |
Mice | 31 | 0.0 |
Monocytes/cytology/*immunology/metabolism | 2 | 16.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Tumor Cells, Cultured | 21 | 0.0 |
Up-Regulation/immunology | 7 | 4.0 |
Antigens, CD1/*analysis | 17 | 80.0 |
Cell Differentiation | 44 | 1.0 |
Epithelium/pathology | 5 | 3.0 |
Langerhans Cells/*pathology | 8 | 61.0 |
Cell Division | 24 | 0.0 |
Child, Preschool | 47 | 0.0 |
Genotype | 5 | 0.0 |
In Situ Hybridization, Fluorescence | 5 | 0.0 |
Mice, Nude | 3 | 0.0 |
Antigens, CD/biosynthesis | 11 | 3.0 |
Dendritic Cells/cytology/*drug effects/immunology | 3 | 25.0 |
Immunoglobulins/biosynthesis | 5 | 4.0 |
Interleukin-4/pharmacology | 30 | 8.0 |
Membrane Glycoproteins/biosynthesis | 7 | 4.0 |
Antigens, CD/*analysis | 19 | 2.0 |
Antigens, CD1/analysis | 49 | 64.0 |
Antigens, CD34/analysis | 11 | 1.0 |
Apoptosis/*drug effects | 4 | 0.0 |
Child | 57 | 0.0 |
Interleukin-7/*pharmacology | 3 | 7.0 |
Neoplasm Staging | 5 | 0.0 |
B-Lymphocytes/immunology | 4 | 0.0 |
Dendritic Cells/cytology/*immunology | 10 | 16.0 |
Flow Cytometry | 82 | 1.0 |
Hematopoietic Stem Cells/cytology/immunology | 3 | 9.0 |
Immunotherapy/*methods | 2 | 1.0 |
T-Lymphocytes/*immunology | 30 | 1.0 |
Biopsy, Needle | 13 | 3.0 |
Diagnosis, Differential | 39 | 1.0 |
Histiocytosis, Sinus/*pathology | 4 | 100.0 |
Prognosis | 7 | 0.0 |
Remission, Spontaneous | 3 | 4.0 |
Antigens, CD40/biosynthesis | 3 | 11.0 |
Biological Markers/analysis | 7 | 0.0 |
Cell Communication/immunology | 4 | 5.0 |
Cell Movement/*immunology | 2 | 2.0 |
HLA-DR Antigens/biosynthesis | 6 | 6.0 |
Receptors, Chemokine/biosynthesis | 2 | 4.0 |
Dendritic Cells/*cytology/*immunology/metabolism | 2 | 18.0 |
Jurkat Cells | 4 | 0.0 |
Ligands | 12 | 0.0 |
Membrane Glycoproteins/metabolism | 8 | 1.0 |
Tumor Necrosis Factor-alpha/metabolism | 7 | 0.0 |
Cell Differentiation/*immunology | 2 | 7.0 |
T-Lymphocytes/immunology | 38 | 2.0 |
Tumor Necrosis Factor-alpha/immunology | 4 | 3.0 |
Androstadienes/*therapeutic use | 3 | 42.0 |
Anti-Inflammatory Agents/*therapeutic use | 2 | 5.0 |
Prospective Studies | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 65 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 5 | 2.0 |
CD4-CD8 Ratio | 5 | 0.0 |
Skin Neoplasms/immunology/*pathology | 2 | 7.0 |
Antigen Presentation/*immunology | 10 | 11.0 |
T-Lymphocytes/cytology/*immunology | 2 | 1.0 |
Cell Adhesion | 11 | 0.0 |
Cell Survival | 10 | 0.0 |
Dendritic Cells/*cytology/immunology | 7 | 16.0 |
Dextrans/metabolism | 2 | 9.0 |
Monocytes/*cytology | 11 | 13.0 |
Pinocytosis | 2 | 16.0 |
T-Lymphocytes/cytology/immunology | 3 | 4.0 |
Antigens, CD1/metabolism | 24 | 60.0 |
Lung Neoplasms/metabolism/*pathology | 2 | 5.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Tumor Markers, Biological/metabolism | 8 | 2.0 |
Antigens, CD/metabolism | 18 | 2.0 |
Cytokines/*metabolism | 3 | 1.0 |
Leukocytes/*immunology | 3 | 2.0 |
Membrane Glycoproteins/analysis | 10 | 3.0 |
Adrenal Cortex Hormones/therapeutic use | 2 | 2.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Eosinophils/pathology | 2 | 5.0 |
Langerhans Cells/pathology | 7 | 41.0 |
Vinblastine/therapeutic use | 3 | 42.0 |
Interleukin-12/biosynthesis | 6 | 6.0 |
Keratinocytes/*immunology/metabolism | 2 | 50.0 |
Langerhans Cells/metabolism/*physiology | 2 | 66.0 |
Monocytes/metabolism | 4 | 1.0 |
Phenotype | 53 | 0.0 |
Up-Regulation | 9 | 0.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Doxorubicin/administration & dosage | 2 | 1.0 |
Karyotyping | 5 | 0.0 |
Dendritic Cells/*cytology/*drug effects/immunology | 2 | 40.0 |
Antigens, CD1/*immunology | 11 | 31.0 |
Antigens, Differentiation/*immunology | 5 | 3.0 |
Breast Neoplasms/immunology/*pathology | 3 | 16.0 |
Cell Count | 32 | 3.0 |
Dendritic Cells/immunology/*pathology | 4 | 26.0 |
Fluorescent Antibody Technique | 24 | 0.0 |
Immunoenzyme Techniques | 59 | 1.0 |
Membrane Glycoproteins/*immunology | 2 | 1.0 |
Age Factors | 5 | 0.0 |
Bone Marrow/pathology | 3 | 0.0 |
Follow-Up Studies | 8 | 0.0 |
Gene Rearrangement, T-Lymphocyte/genetics | 2 | 11.0 |
Survival Rate | 2 | 0.0 |
Dendritic Cells/*cytology/drug effects/*immunology | 5 | 50.0 |
Fetal Blood/*cytology/drug effects/*immunology | 2 | 50.0 |
In Vitro | 18 | 0.0 |
Dendritic Cells/*pathology | 9 | 24.0 |
Antibodies/pharmacology | 2 | 0.0 |
Antigen Presentation | 19 | 6.0 |
Biological Transport | 3 | 0.0 |
Lymphocyte Activation | 36 | 1.0 |
Microscopy, Fluorescence | 7 | 0.0 |
Monocytes/cytology/immunology | 2 | 5.0 |
Stem Cells/immunology | 2 | 6.0 |
Antigens, CD14/analysis | 13 | 11.0 |
B-Lymphocytes/pathology | 4 | 4.0 |
Spleen/cytology | 2 | 1.0 |
Antigens, Neoplasm/immunology | 2 | 1.0 |
Dendritic Cells/*physiology | 8 | 10.0 |
Fetal Blood/*immunology | 3 | 3.0 |
*Immunotherapy | 4 | 2.0 |
T-Lymphocytes, Cytotoxic/immunology | 5 | 1.0 |
Langerhans Cells/*metabolism/physiology | 2 | 100.0 |
Cell Differentiation/*drug effects | 8 | 5.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 7 | 4.0 |
Reference Values | 8 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 4 | 0.0 |
Antigens, CD/*metabolism | 7 | 1.0 |
Antigens, CD80/*metabolism | 3 | 5.0 |
Langerhans Cells/*metabolism | 12 | 63.0 |
Membrane Glycoproteins/*metabolism | 4 | 0.0 |
Dendritic Cells/metabolism | 3 | 6.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Skin/metabolism/pathology | 3 | 6.0 |
Staining and Labeling | 11 | 1.0 |
Tissue Distribution | 3 | 0.0 |
Proviruses/isolation & purification | 2 | 11.0 |
Survival Analysis | 4 | 0.0 |
Aged, 80 and over | 31 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 10 | 1.0 |
Cell Division/immunology | 7 | 2.0 |
Immunoglobulins/analysis | 6 | 2.0 |
Lymphocytes, Tumor-Infiltrating/immunology | 2 | 5.0 |
Neoplasm Invasiveness | 4 | 0.0 |
T-Lymphocyte Subsets/*immunology | 5 | 0.0 |
Cell Communication | 3 | 1.0 |
Epidermis/*cytology/immunology | 2 | 66.0 |
Fetal Blood/cytology | 13 | 6.0 |
Langerhans Cells/*cytology/immunology | 5 | 100.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Histiocytosis/*pathology | 2 | 100.0 |
Sarcoma/*pathology | 2 | 14.0 |
Skin Neoplasms/*pathology | 4 | 4.0 |
Bronchoalveolar Lavage Fluid/cytology | 2 | 1.0 |
Bronchoscopy | 3 | 4.0 |
Lung/pathology/radiography | 2 | 25.0 |
Smoking/adverse effects | 4 | 1.0 |
Adjuvants, Immunologic/*administration & dosage | 2 | 6.0 |
Cell Differentiation/drug effects/immunology | 10 | 14.0 |
Drug Synergism | 4 | 0.0 |
Interferon-beta/*administration & dosage | 2 | 28.0 |
Multiple Sclerosis, Chronic Progressive/*drug therapy/immunology | 2 | 50.0 |
Multiple Sclerosis, Relapsing-Remitting/*drug therapy/immunology | 2 | 33.0 |
Receptors, Interleukin-3/analysis | 2 | 18.0 |
Th2 Cells/cytology/immunology | 2 | 40.0 |
Autoantigens/immunology | 2 | 1.0 |
CD4-Positive T-Lymphocytes/*immunology | 5 | 0.0 |
Cell Separation | 22 | 2.0 |
Cytokines/biosynthesis | 11 | 2.0 |
Isoantigens/immunology | 3 | 3.0 |
Lipopolysaccharides/pharmacology | 9 | 0.0 |
Lymphocyte Activation/*immunology | 2 | 0.0 |
Monocytes/*cytology/*immunology/metabolism | 2 | 66.0 |
Phagocytosis | 6 | 1.0 |
Mast Cells/drug effects/pathology | 2 | 66.0 |
Interleukin-13/pharmacology | 3 | 7.0 |
*Receptors, Chemokine | 2 | 2.0 |
Th2 Cells/*immunology | 2 | 1.0 |
Cell Separation/*methods | 4 | 2.0 |
Fetal Blood/*cytology | 10 | 5.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
HLA-DR Antigens/analysis | 29 | 4.0 |
Antigens, Neoplasm/analysis | 5 | 1.0 |
Magnetic Resonance Imaging | 8 | 0.0 |
Organelles/ultrastructure | 2 | 11.0 |
Treatment Outcome | 9 | 0.0 |
Tumor Markers, Biological/analysis | 8 | 1.0 |
CD8-Positive T-Lymphocytes/*immunology | 5 | 1.0 |
Cytomegalovirus/isolation & purification | 2 | 12.0 |
Lymphocyte Count | 3 | 0.0 |
Thymus Gland/immunology | 5 | 7.0 |
Hematopoietic Stem Cells | 2 | 3.0 |
Monocytes | 2 | 2.0 |
Transfection | 13 | 0.0 |
Endocytosis | 7 | 1.0 |
Monocytes/physiology | 2 | 1.0 |
Immunohistochemistry/methods | 7 | 1.0 |
Langerhans Cells/metabolism/*pathology | 3 | 100.0 |
Receptors, IgE/*metabolism | 3 | 8.0 |
Severity of Illness Index | 3 | 0.0 |
Antibodies, Monoclonal/analysis | 2 | 2.0 |
Cell Line, Transformed | 2 | 0.0 |
Precipitin Tests | 7 | 0.0 |
Fluorescent Antibody Technique, Indirect | 9 | 1.0 |
K562 Cells | 2 | 0.0 |
Down-Regulation | 5 | 0.0 |
Virus Replication | 7 | 0.0 |
Biopsy/methods | 4 | 8.0 |
Immunosuppressive Agents/therapeutic use | 2 | 0.0 |
Tomography, X-Ray Computed | 11 | 1.0 |
Antigens, CD1/*genetics | 5 | 35.0 |
Administration, Topical | 7 | 6.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
*Photochemotherapy | 2 | 4.0 |
Antigens, CD3/analysis | 5 | 2.0 |
Antigens, CD4/analysis | 7 | 1.0 |
Antigens, CD8/analysis | 4 | 1.0 |
Fetus | 2 | 0.0 |
Frozen Sections | 4 | 4.0 |
Gestational Age | 5 | 0.0 |
Paraffin Embedding | 3 | 1.0 |
*Cancer Vaccines | 2 | 7.0 |
Cell Culture Techniques | 11 | 2.0 |
*Dendritic Cells | 2 | 18.0 |
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2.0 |
Immunophenotyping/methods | 2 | 4.0 |
Antigens, CD40/analysis | 2 | 8.0 |
Antigens, CD80/analysis | 3 | 6.0 |
Enzyme-Linked Immunosorbent Assay | 7 | 0.0 |
Histiocytosis, Langerhans-Cell/*complications/pathology | 2 | 66.0 |
Antigens, CD1/*blood | 2 | 100.0 |
Antigens, CD14/*blood | 2 | 6.0 |
Infant, Newborn | 29 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 3 | 0.0 |
Antigens/immunology | 2 | 1.0 |
Dendritic Cells/cytology/drug effects/*immunology | 4 | 18.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
Th1 Cells/immunology | 2 | 1.0 |
Antigens, CD1/metabolism/*physiology | 2 | 100.0 |
Dendritic Cells/immunology | 9 | 6.0 |
Epithelial Cells/immunology | 2 | 5.0 |
Culture Media, Conditioned | 2 | 0.0 |
Lymphocyte Activation/immunology | 9 | 1.0 |
Solubility | 6 | 0.0 |
Up-Regulation/*immunology | 2 | 3.0 |
Antigens, CD1/*metabolism | 15 | 46.0 |
Dendritic Cells/*cytology/immunology/metabolism | 4 | 50.0 |
Phagocytosis/immunology | 2 | 3.0 |
E-Selectin/analysis | 3 | 15.0 |
Intercellular Adhesion Molecule-1/analysis | 9 | 8.0 |
Interleukins/analysis | 2 | 6.0 |
Skin/*chemistry/pathology | 2 | 28.0 |
Back | 2 | 33.0 |
Fatal Outcome | 4 | 0.0 |
Epidermis/*cytology | 4 | 13.0 |
T-Lymphocytes/cytology | 2 | 2.0 |
Interleukin-10/metabolism | 2 | 3.0 |
Interleukin-12/metabolism | 2 | 3.0 |
Dendritic Cells/*immunology/metabolism | 7 | 15.0 |
Immunoglobulins/*analysis | 2 | 2.0 |
Membrane Glycoproteins/*analysis | 5 | 3.0 |
Monocytes/immunology | 9 | 2.0 |
Receptor, Anaphylatoxin C5a | 2 | 10.0 |
Receptors, Complement/*metabolism | 2 | 1.0 |
Skin/*immunology | 10 | 9.0 |
Histiocytosis, Langerhans-Cell/*pathology | 6 | 60.0 |
Lung/*pathology | 3 | 10.0 |
Cytotoxicity, Immunologic | 4 | 0.0 |
HLA-DR Antigens/metabolism | 10 | 7.0 |
Interferon Type II/secretion | 4 | 3.0 |
Leukocytes, Mononuclear/immunology/pathology | 2 | 22.0 |
Tumor Necrosis Factor-alpha/pharmacology | 17 | 1.0 |
Apoptosis | 5 | 0.0 |
Dendritic Cells/*virology | 3 | 21.0 |
Genes, Viral | 2 | 0.0 |
Antigens, Viral/analysis | 2 | 2.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 4 | 4.0 |
*Immunophenotyping | 8 | 4.0 |
S100 Proteins/metabolism | 12 | 11.0 |
Skin Neoplasms/chemistry/*pathology | 2 | 4.0 |
Dendritic Cells/immunology/*physiology | 2 | 28.0 |
Integrin alphaXbeta2/analysis | 2 | 13.0 |
*Lectins, C-Type | 8 | 4.0 |
*Mannose-Binding Lectins | 8 | 16.0 |
Statistics, Nonparametric | 4 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
*Cytotoxicity, Immunologic | 2 | 0.0 |
*Antigen Presentation | 14 | 8.0 |
Allergens/*immunology | 2 | 2.0 |
Epidermis/immunology | 7 | 33.0 |
Langerhans Cells/*drug effects/immunology | 2 | 50.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Lymph Nodes/pathology | 7 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 2 | 1.0 |
B-Lymphocytes/cytology | 2 | 2.0 |
Fetal Blood | 2 | 1.0 |
Leukocytes/metabolism | 2 | 1.0 |
Thymus Gland/cytology/*metabolism | 2 | 15.0 |
Dendritic Cells/metabolism/pathology | 4 | 50.0 |
Antigens, Differentiation, Myelomonocytic/metabolism | 5 | 3.0 |
*Coronary Artery Bypass | 2 | 2.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
Thigh | 2 | 7.0 |
Adenoviridae/*genetics | 2 | 0.0 |
Dendritic Cells/*metabolism | 4 | 6.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Genetic Vectors | 5 | 0.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Monocytes/*metabolism | 3 | 0.0 |
Cell Movement/immunology | 3 | 3.0 |
Dendritic Cells/immunology/pathology | 6 | 31.0 |
Immunity, Cellular | 4 | 0.0 |
Immunity, Natural | 2 | 0.0 |
Injections, Intradermal | 2 | 4.0 |
Lymphocyte Subsets/pathology | 2 | 8.0 |
Receptors, CCR5/biosynthesis | 2 | 5.0 |
Up-Regulation/drug effects/immunology | 4 | 10.0 |
p38 Mitogen-Activated Protein Kinases | 3 | 0.0 |
Endocytosis/physiology | 2 | 2.0 |
Antigens, CD14/metabolism | 3 | 2.0 |
Biological Markers | 13 | 0.0 |
Cell Division/drug effects | 9 | 0.0 |
CD8-Positive T-Lymphocytes/immunology | 5 | 1.0 |
DNA, Viral/analysis | 4 | 1.0 |
Langerhans Cells/immunology | 11 | 32.0 |
Mucous Membrane/immunology | 2 | 7.0 |
Antibodies, Monoclonal/diagnostic use | 12 | 1.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Microscopy, Immunoelectron | 6 | 1.0 |
Models, Biological | 6 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Protein Transport | 2 | 0.0 |
Cell Survival/immunology | 3 | 5.0 |
Cytokines/pharmacology | 7 | 1.0 |
Adjuvants, Immunologic/pharmacology | 2 | 2.0 |
Antigen Presentation/drug effects | 4 | 12.0 |
Apoptosis/drug effects | 3 | 0.0 |
Dendritic Cells/*cytology | 17 | 30.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Monocytes/cytology | 4 | 3.0 |
Keratin/metabolism | 3 | 2.0 |
Skin Neoplasms/metabolism/*pathology | 2 | 5.0 |
Langerhans Cells/metabolism/pathology | 3 | 75.0 |
Lymphocytes/metabolism/pathology | 2 | 11.0 |
Antigens, CD3/biosynthesis | 3 | 5.0 |
Antigens, CD34/biosynthesis | 3 | 3.0 |
Antigens, CD4/biosynthesis | 3 | 3.0 |
Antigens, CD8/biosynthesis | 2 | 5.0 |
Epithelial Cells/*immunology | 2 | 10.0 |
Antigens, CD40/immunology | 2 | 3.0 |
Dendritic Cells/cytology/immunology/*virology | 2 | 66.0 |
Cell Movement/physiology | 4 | 1.0 |
Culture Techniques | 4 | 0.0 |
Langerhans Cells/*cytology/immunology/physiology | 2 | 100.0 |
Reproducibility of Results | 4 | 0.0 |
Staining and Labeling/methods | 2 | 1.0 |
Desmopressin/therapeutic use | 2 | 6.0 |
Antigen Presentation/immunology | 6 | 7.0 |
Intracellular Fluid/immunology/metabolism | 2 | 6.0 |
Cell Nucleus/ultrastructure | 4 | 3.0 |
Chemotaxis, Leukocyte/immunology | 2 | 3.0 |
Mice, Inbred BALB C | 7 | 0.0 |
Cell Lineage | 8 | 1.0 |
Gene Expression Regulation | 9 | 0.0 |
Hematopoietic Stem Cells/cytology | 5 | 5.0 |
Reverse Transcriptase Polymerase Chain Reaction | 8 | 0.0 |
Thymus Gland/*cytology | 4 | 7.0 |
Antigen-Presenting Cells/*immunology | 2 | 1.0 |
Cytotoxicity Tests, Immunologic | 3 | 0.0 |
Interleukin-4/therapeutic use | 2 | 28.0 |
*Lymphocyte Activation | 6 | 0.0 |
Antigen-Presenting Cells/cytology | 2 | 25.0 |
Intestinal Mucosa/*immunology | 2 | 2.0 |
Antigens, CD34 | 11 | 1.0 |
Cryopreservation | 3 | 2.0 |
Culture Media | 7 | 1.0 |
Immunotherapy/methods | 3 | 3.0 |
Recurrence | 4 | 0.0 |
Cadherins/*metabolism | 2 | 2.0 |
Cell Adhesion Molecules/biosynthesis | 4 | 4.0 |
Cell Aggregation | 2 | 1.0 |
Culture Media, Serum-Free | 3 | 0.0 |
Lymphocyte Function-Associated Antigen-1/immunology | 2 | 7.0 |
Membrane Proteins/pharmacology | 2 | 4.0 |
Stem Cell Factor/pharmacology | 4 | 2.0 |
Transforming Growth Factor beta/pharmacology | 4 | 1.0 |
RNA, Viral/analysis | 3 | 1.0 |
Antigens, CD80/metabolism | 2 | 2.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Isoantigens | 2 | 7.0 |
Stem Cells/cytology/drug effects/immunology | 2 | 50.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Immunophenotyping/*methods | 2 | 2.0 |
Receptors, Antigen, T-Cell, gamma-delta/analysis | 3 | 8.0 |
Antigens, Surface/immunology | 5 | 2.0 |
Macrophages/immunology | 7 | 2.0 |
Melanoma/*immunology/pathology | 2 | 8.0 |
T-Lymphocyte Subsets/immunology | 7 | 1.0 |
T-Lymphocytes/*immunology/metabolism | 3 | 1.0 |
Antigens, CD40/*metabolism | 3 | 6.0 |
Histiocytosis, Langerhans-Cell/*immunology | 3 | 50.0 |
Immune System/*cytology | 2 | 50.0 |
Langerhans Cells/cytology | 2 | 40.0 |
Macrophages/cytology | 4 | 5.0 |
Antigens, CD1/*biosynthesis | 5 | 50.0 |
Dendritic Cells/*immunology/*metabolism | 3 | 17.0 |
Luminescent Proteins/biosynthesis/genetics | 2 | 8.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Signal Transduction/immunology | 2 | 0.0 |
Antigens, Neoplasm/*immunology | 2 | 1.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Dextrans | 2 | 4.0 |
Monocytes/*immunology | 6 | 1.0 |
Stem Cells/cytology/immunology | 2 | 11.0 |
Cytokines/*pharmacology | 3 | 0.0 |
Dendritic Cells/*cytology/immunology/physiology | 2 | 50.0 |
Antigens, CD1/immunology | 4 | 36.0 |
Antigens, CD34/*immunology | 3 | 4.0 |
Antigens, CD80/immunology | 4 | 6.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/immunology | 2 | 7.0 |
HLA-D Antigens/*immunology | 2 | 3.0 |
Interleukin-4/immunology | 3 | 5.0 |
Antigens, CD/immunology | 14 | 2.0 |
Endosomes/immunology | 2 | 28.0 |
Histocompatibility Antigens Class I/*analysis | 4 | 8.0 |
Dendritic Cells/metabolism/*pathology | 2 | 22.0 |
T-Lymphocytes/*pathology | 2 | 2.0 |
Immunization | 2 | 0.0 |
Kinetics | 5 | 0.0 |
Membrane Glycoproteins/immunology | 6 | 3.0 |
Disease Progression | 5 | 0.0 |
Antigens, Differentiation/analysis | 4 | 1.0 |
Neoplasm Metastasis | 2 | 0.0 |
Radiography, Thoracic | 2 | 5.0 |
Transglutaminases/metabolism | 2 | 10.0 |
DNA Primers/chemistry | 3 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Antigens, CD34/immunology | 2 | 3.0 |
Organ Culture Techniques | 8 | 2.0 |
Skin/*cytology/immunology | 3 | 37.0 |
Antigens, CD/blood | 3 | 1.0 |
Interleukin-2/biosynthesis | 2 | 0.0 |
Antigens, Bacterial/*immunology | 4 | 3.0 |
Antigens, CD1/*immunology/metabolism | 2 | 40.0 |
*Endocytosis | 2 | 1.0 |
Hela Cells | 4 | 0.0 |
Lipids/*immunology | 2 | 25.0 |
Macrophages/pathology | 2 | 1.0 |
Combined Modality Therapy | 3 | 0.0 |
Glycoproteins/*metabolism | 2 | 1.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Antibodies, Monoclonal/immunology | 15 | 0.0 |
Cytokines/immunology | 3 | 2.0 |
Dendritic Cells/drug effects/*immunology | 6 | 23.0 |
Drug Therapy, Combination | 3 | 0.0 |
Histocompatibility Antigens Class II/immunology | 8 | 4.0 |
Peptides/immunology | 3 | 2.0 |
Antibody Specificity | 8 | 0.0 |
Antigens, CD1/chemistry/*metabolism | 2 | 66.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 2 | 1.0 |
Histocompatibility Antigens Class II/analysis | 4 | 2.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis | 3 | 6.0 |
*Protein Biosynthesis | 2 | 0.0 |
Lymph Nodes/*pathology | 4 | 4.0 |
Biological Transport/immunology | 2 | 7.0 |
Receptors, Cell Surface/biosynthesis | 2 | 5.0 |
Antigens/metabolism | 2 | 3.0 |
Immunosuppressive Agents/pharmacology | 3 | 1.0 |
Analysis of Variance | 3 | 0.0 |
Antigens, Surface/analysis | 9 | 2.0 |
Case-Control Studies | 8 | 0.0 |
Collagen/analysis | 2 | 2.0 |
Epithelium/immunology | 6 | 4.0 |
Periodontitis/*immunology | 2 | 11.0 |
Calcium Signaling | 2 | 2.0 |
Receptors, Antigen, T-Cell, alpha-beta | 2 | 5.0 |
Superantigens/*immunology | 2 | 2.0 |
Fluorescein-5-isothiocyanate | 2 | 1.0 |
Antigens, CD1 | 68 | 71.0 |
Antigens, CD34/*analysis | 6 | 2.0 |
Fetal Blood/cytology/*immunology | 3 | 15.0 |
Hematopoietic Stem Cells/*cytology | 6 | 2.0 |
Macrophages/*cytology | 4 | 12.0 |
Cell Culture Techniques/*methods | 5 | 5.0 |
Lymphocyte Activation/drug effects | 5 | 0.0 |
PUVA Therapy | 4 | 28.0 |
Skin/*pathology | 2 | 2.0 |
*Patch Tests | 2 | 16.0 |
Dendritic Cells/pathology | 6 | 26.0 |
HIV Core Protein p24/analysis | 3 | 4.0 |
Histiocytes/pathology | 5 | 20.0 |
T-Lymphocytes/pathology | 4 | 3.0 |
Skin Diseases/complications/*pathology | 2 | 66.0 |
Skin Neoplasms/pathology | 3 | 13.0 |
Skin/pathology/ultrastructure | 3 | 16.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 3 | 1.0 |
Histiocytosis, Langerhans-Cell/*immunology/pathology | 3 | 60.0 |
Antigens, Differentiation/metabolism | 2 | 1.0 |
Histocompatibility Antigens Class I/immunology | 5 | 4.0 |
Tumor Markers, Biological | 3 | 0.0 |
Antigens, Differentiation/immunology | 4 | 3.0 |
Dendritic Cells/*immunology/*pathology | 2 | 40.0 |
Immunoglobulins/immunology | 3 | 6.0 |
Antibodies, Monoclonal | 29 | 1.0 |
Dermatitis, Atopic/*immunology/*pathology | 2 | 100.0 |
T-Lymphocytes/immunology/pathology | 3 | 5.0 |
Antigens, Surface/metabolism | 6 | 5.0 |
Thymoma/classification/*metabolism/pathology | 2 | 100.0 |
Thymus Neoplasms/classification/*metabolism/pathology | 2 | 100.0 |
Fibroblasts/cytology | 2 | 0.0 |
Skin Diseases/*pathology | 7 | 28.0 |
Antigens, CD/immunology/metabolism | 3 | 5.0 |
Antibodies, Monoclonal/*therapeutic use | 2 | 0.0 |
Antigens, CD/blood/immunology | 2 | 22.0 |
Immunosuppressive Agents/*therapeutic use | 2 | 1.0 |
Antigens, Bacterial/chemistry/metabolism | 2 | 100.0 |
Autoimmunity | 2 | 1.0 |
Models, Molecular | 5 | 0.0 |
Mycobacterium/immunology | 2 | 15.0 |
Protein Conformation | 5 | 0.0 |
Langerhans Cells/*cytology/physiology | 2 | 100.0 |
Myelodysplastic Syndromes/*pathology | 3 | 10.0 |
Killer Cells, Natural/immunology | 4 | 0.0 |
Interleukin-4/*metabolism/pharmacology | 2 | 33.0 |
Cytokines/metabolism | 2 | 0.0 |
Dendritic Cells/*chemistry | 2 | 22.0 |
Histiocytosis, Langerhans-Cell/*pathology/therapy | 2 | 66.0 |
*Biological Markers | 2 | 1.0 |
Giant Cells/metabolism/*pathology/virology | 2 | 100.0 |
HIV Core Protein p24/metabolism | 3 | 7.0 |
HIV Infections/*complications/metabolism | 2 | 66.0 |
Herpesviridae Infections/complications/metabolism | 2 | 100.0 |
Herpesvirus 4, Human/*pathogenicity | 2 | 18.0 |
Hyperplasia | 5 | 1.0 |
In Situ Hybridization | 5 | 0.0 |
Tonsil/metabolism/*pathology/*virology | 2 | 100.0 |
Tumor Virus Infections/complications/metabolism | 2 | 100.0 |
Base Sequence | 20 | 0.0 |
Ultraviolet Rays/*adverse effects | 2 | 4.0 |
Cell Count/radiation effects | 2 | 100.0 |
*Ultraviolet Rays | 4 | 1.0 |
Intercellular Adhesion Molecule-1/metabolism | 2 | 1.0 |
Ultraviolet Rays/adverse effects | 2 | 3.0 |
Skin/immunology | 4 | 4.0 |
Muramidase/analysis | 3 | 11.0 |
Antigens, CD4/immunology | 3 | 1.0 |
Leukocytes, Mononuclear/*immunology | 2 | 1.0 |
Superantigens/immunology | 2 | 4.0 |
Anti-Inflammatory Agents/therapeutic use | 2 | 2.0 |
Double-Blind Method | 5 | 0.0 |
Glucocorticoids | 2 | 6.0 |
Histiocytosis, Langerhans-Cell/*diagnosis/pathology | 2 | 100.0 |
Lectins, C-Type/immunology/metabolism | 2 | 40.0 |
Mannose-Binding Lectins/immunology/metabolism | 2 | 66.0 |
Cheek | 2 | 7.0 |
Amino Acid Sequence | 18 | 0.0 |
Molecular Sequence Data | 23 | 0.0 |
Antigens, CD34/blood | 2 | 3.0 |
HLA-DR Antigens/immunology | 9 | 4.0 |
Protein p53/analysis | 2 | 0.0 |
Skin/*drug effects/pathology | 2 | 33.0 |
Gingiva/*pathology | 2 | 66.0 |
Flow Cytometry/methods | 6 | 2.0 |
Monocytes/cytology/*immunology | 4 | 11.0 |
Antigens, CD14/biosynthesis | 3 | 4.0 |
Antigens, CD80/biosynthesis | 2 | 3.0 |
Histocompatibility Antigens Class I/biosynthesis | 2 | 4.0 |
Monocytes/cytology/drug effects/immunology | 2 | 20.0 |
Langerhans Cells/cytology/*immunology | 3 | 60.0 |
Antigens, CD/analysis/*immunology | 2 | 5.0 |
DNA Mutational Analysis | 2 | 0.0 |
Dendritic Cells/*drug effects | 2 | 18.0 |
Recombinant Proteins/pharmacology | 6 | 0.0 |
Immunoglobulin E/analysis | 2 | 3.0 |
Nasal Mucosa/*pathology | 2 | 40.0 |
Antigens, CD30/analysis | 3 | 8.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
Antigens, CD40/metabolism | 2 | 3.0 |
CD40 Ligand | 3 | 1.0 |
Down-Regulation/drug effects/immunology | 2 | 10.0 |
Bladder Neoplasms/*immunology | 3 | 14.0 |
Carcinoma, Transitional Cell/*immunology | 2 | 22.0 |
Antigens, CD34/metabolism | 5 | 1.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2.0 |
Models, Immunological | 2 | 0.0 |
Antibodies, Monoclonal/pharmacology | 5 | 0.0 |
Lymphocytes/immunology | 3 | 0.0 |
Neoplasms/immunology | 2 | 3.0 |
Antibody Formation | 4 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Graft vs Host Disease/immunology | 2 | 6.0 |
Immunomagnetic Separation | 2 | 1.0 |
Cell Membrane/immunology | 3 | 1.0 |
Cell Separation/methods | 4 | 2.0 |
Interleukin-4/secretion | 2 | 4.0 |
Macrophages/*pathology | 3 | 5.0 |
Lymphocytes/*immunology | 4 | 0.0 |
Dendritic Cells/*immunology/pathology | 5 | 29.0 |
Immunoglobulins/metabolism | 2 | 1.0 |
Skin/immunology/pathology | 3 | 7.0 |
Cell Nucleus/pathology | 2 | 2.0 |
Extracellular Matrix/pathology | 2 | 18.0 |
Antibodies, Blocking/pharmacology | 2 | 2.0 |
Antigens, CD1/*physiology | 2 | 20.0 |
Chromatography, Gel | 2 | 0.0 |
Macrophages/metabolism/pathology | 2 | 7.0 |
Transglutaminases/analysis | 7 | 20.0 |
Cytoplasm/ultrastructure | 3 | 4.0 |
Radiation Dosage | 2 | 2.0 |
Cell Movement | 10 | 1.0 |
T-Lymphocytes/*cytology | 2 | 2.0 |
Cattle | 2 | 0.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Dendritic Cells/immunology/microbiology | 2 | 100.0 |
Receptors, Antigen, T-Cell, gamma-delta/*immunology | 3 | 6.0 |
HLA Antigens/metabolism | 2 | 6.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Cell Differentiation/drug effects/physiology | 2 | 2.0 |
Interleukin-10/*pharmacology | 3 | 3.0 |
Administration, Inhalation | 2 | 1.0 |
Dendritic Cells/*drug effects/immunology | 2 | 14.0 |
Antigens, CD/*immunology | 6 | 1.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
HLA-DR Antigens/*immunology | 2 | 1.0 |
Keratinocytes/cytology | 2 | 5.0 |
HLA Antigens/analysis | 5 | 2.0 |
Skin/cytology/immunology | 3 | 16.0 |
Hematopoietic Stem Cells/*physiology | 3 | 2.0 |
Microscopy, Confocal | 4 | 0.0 |
Skin/cytology/*metabolism | 3 | 8.0 |
Risk Factors | 2 | 0.0 |
Histiocytosis, Langerhans-Cell/complications/*pathology | 2 | 100.0 |
Macrophages/immunology/pathology | 2 | 6.0 |
Receptors, Cell Surface/metabolism | 4 | 0.0 |
Cell Adhesion Molecules/*analysis | 3 | 2.0 |
Skin/chemistry/pathology | 2 | 8.0 |
Flow Cytometry/*methods | 3 | 1.0 |
Hematopoiesis/*drug effects | 2 | 2.0 |
Hematopoietic Stem Cells/cytology/*drug effects | 2 | 3.0 |
Lymphocyte Subsets/*immunology | 2 | 1.0 |
Neoplasm Recurrence, Local | 3 | 0.0 |
Antibodies, Monoclonal/*immunology | 3 | 0.0 |
Cats | 2 | 0.0 |
Dogs | 2 | 0.0 |
Guinea Pigs | 2 | 0.0 |
Molecular Weight | 7 | 0.0 |
Rabbits | 2 | 0.0 |
Rats | 3 | 0.0 |
Species Specificity | 3 | 0.0 |
Langerhans Cells/*immunology | 19 | 47.0 |
*Antigens, CD34 | 4 | 5.0 |
Cell Size | 2 | 0.0 |
Keratinocytes/chemistry | 2 | 11.0 |
Vascular Cell Adhesion Molecule-1/analysis | 3 | 7.0 |
*Evolution, Molecular | 2 | 0.0 |
Exons | 2 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Pilot Projects | 2 | 0.0 |
Macrophages/immunology/metabolism | 2 | 4.0 |
Skin/*cytology | 3 | 6.0 |
Receptors, Interleukin-2/metabolism | 2 | 1.0 |
Antigen-Presenting Cells/*physiology | 3 | 8.0 |
Skin/cytology/*immunology | 4 | 40.0 |
Antigen-Presenting Cells/pathology | 2 | 40.0 |
Epithelium/metabolism/pathology | 2 | 3.0 |
Antigens, CD14/immunology | 2 | 3.0 |
Transcription, Genetic | 2 | 0.0 |
Interleukin-4/biosynthesis | 2 | 1.0 |
Endothelium, Vascular/pathology | 2 | 1.0 |
Antigens, CD | 2 | 1.0 |
Membrane Glycoproteins | 2 | 4.0 |
Interleukin-10/*metabolism | 3 | 10.0 |
*Antigens, CD | 3 | 0.0 |
Langerhans Cells/chemistry | 2 | 66.0 |
Leukocytes, Mononuclear/cytology | 2 | 4.0 |
Macrophages/cytology/immunology | 2 | 10.0 |
Radioimmunoassay | 2 | 0.0 |
Nevus/metabolism/pathology | 2 | 100.0 |
Immunotherapy | 2 | 0.0 |
Antigens, CD11/analysis | 3 | 10.0 |
Epidermis/pathology | 3 | 9.0 |
Langerhans Cells/immunology/pathology | 5 | 83.0 |
Leukocytes/immunology/pathology | 2 | 25.0 |
Lymphocyte Function-Associated Antigen-1/analysis | 4 | 9.0 |
HIV-1/*immunology | 2 | 0.0 |
Histocompatibility Antigens Class I/analysis | 2 | 2.0 |
T-Lymphocytes, Cytotoxic/drug effects/*immunology | 2 | 9.0 |
Disease Models, Animal | 2 | 0.0 |
Langerhans Cells/*immunology/ultrastructure | 5 | 55.0 |
Langerhans Cells/*physiology | 4 | 50.0 |
Hematopoietic Stem Cells/cytology/*immunology | 2 | 4.0 |
Mutation | 2 | 0.0 |
Bone Marrow Cells | 2 | 0.0 |
Transduction, Genetic | 2 | 0.0 |
HLA-DR Antigens/*analysis | 6 | 3.0 |
Keratinocytes/cytology/*immunology | 2 | 40.0 |
Cytopathogenic Effect, Viral | 2 | 1.0 |
Immune Tolerance | 4 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*physiology | 2 | 11.0 |
Tumor Necrosis Factor-alpha/*physiology | 2 | 0.0 |
Skin/immunology/*pathology | 2 | 12.0 |
Langerhans Cells/immunology/*pathology | 5 | 50.0 |
Transplantation, Homologous | 4 | 0.0 |
Cell Adhesion Molecules/analysis | 2 | 1.0 |
Blotting, Western | 2 | 0.0 |
Cell Cycle | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Interleukin-8/analysis | 2 | 4.0 |
Keratin/analysis | 3 | 1.0 |
Keratinocytes/pathology | 3 | 12.0 |
Proliferating Cell Nuclear Antigen/analysis | 2 | 0.0 |
Protein Precursors/analysis | 2 | 4.0 |
Receptors, Tumor Necrosis Factor/analysis | 2 | 3.0 |
Histiocytosis, Langerhans-Cell/metabolism/*pathology | 3 | 60.0 |
HIV-1/*growth & development | 2 | 3.0 |
Cloning, Molecular | 7 | 0.0 |
Epithelial Cells | 9 | 1.0 |
Retroviridae/genetics | 2 | 0.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Protein Kinase C/*metabolism | 2 | 0.0 |
B-Lymphocytes/*immunology | 4 | 0.0 |
Dendritic Cells/classification/*immunology | 3 | 42.0 |
Lymphoid Tissue/immunology | 2 | 5.0 |
Melanocytes/*metabolism | 2 | 5.0 |
Leukocyte L1 Antigen Complex | 2 | 3.0 |
Neural Cell Adhesion Molecules/analysis | 2 | 13.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Interleukin-4/*pharmacology | 2 | 0.0 |
Cell Adhesion/immunology | 3 | 1.0 |
Cell Adhesion Molecules/*biosynthesis | 2 | 2.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Interferon Type II/metabolism | 2 | 0.0 |
Interleukin-1/metabolism | 2 | 0.0 |
Mice, SCID | 6 | 0.0 |
Antigens, CD/*biosynthesis | 6 | 3.0 |
DNA Primers | 4 | 0.0 |
*Homeodomain Proteins | 2 | 0.0 |
Breast Neoplasms/*immunology/pathology | 2 | 8.0 |
Dinoprostone/pharmacology | 2 | 2.0 |
*Papillomavirus, Human | 2 | 6.0 |
Skin/cytology | 2 | 1.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Monocytes/drug effects/*immunology | 3 | 4.0 |
Bronchoalveolar Lavage Fluid/*cytology | 3 | 6.0 |
Dendritic Cells/drug effects/immunology/*metabolism | 2 | 40.0 |
Histiocytosis, Langerhans-Cell/diagnosis | 2 | 100.0 |
Risk Assessment | 2 | 0.0 |
Actins/analysis | 2 | 1.0 |
Receptors, Interleukin-2/analysis | 3 | 1.0 |
Histiocytosis, Langerhans-Cell/*metabolism/pathology | 2 | 50.0 |
HLA-DR Antigens/*metabolism | 2 | 3.0 |
Langerhans Cells/*cytology | 3 | 75.0 |
Hematopoietic Stem Cells/*cytology/immunology | 2 | 2.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Epidermis/cytology/metabolism | 3 | 16.0 |
*Antigens, Differentiation | 2 | 2.0 |
Dermatitis, Allergic Contact/immunology | 2 | 40.0 |
Dermatitis, Atopic/immunology | 2 | 15.0 |
Langerhans Cells/*chemistry/immunology | 2 | 100.0 |
Skin Diseases/immunology | 2 | 20.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
Signal Transduction | 2 | 0.0 |
Langerhans Cells/*enzymology/immunology | 2 | 100.0 |
Connective Tissue/immunology/pathology | 2 | 28.0 |
Epithelium/immunology/pathology | 3 | 11.0 |
Mouth Mucosa/immunology/pathology | 3 | 30.0 |
Psoriasis/immunology/*pathology | 2 | 25.0 |
Langerhans Cells/cytology/*metabolism | 2 | 50.0 |
S100 Proteins/*analysis | 4 | 8.0 |
Image Processing, Computer-Assisted | 3 | 0.0 |
Epidermis/cytology | 3 | 8.0 |
*Bone Marrow Cells | 3 | 1.0 |
Leukocytes, Mononuclear/*cytology | 2 | 9.0 |
Keratinocytes/immunology | 4 | 16.0 |
Lectins/chemistry | 2 | 18.0 |
Interleukin-4/metabolism | 2 | 2.0 |
Histocompatibility Antigens Class II/metabolism | 3 | 3.0 |
Langerhans Cells/cytology/immunology | 2 | 40.0 |
Cell Count/methods | 2 | 3.0 |
Dendritic Cells/*drug effects/metabolism | 2 | 25.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
HLA-D Antigens/analysis | 2 | 3.0 |
Epidermis/immunology/pathology | 2 | 33.0 |
Skin Diseases/*immunology | 2 | 9.0 |
Smoking | 3 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Keratinocytes/immunology/pathology | 3 | 50.0 |
Periodontitis/*immunology/pathology | 2 | 28.0 |
Antigens, CD/*genetics | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Genes, Structural | 2 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
beta 2-Microglobulin/metabolism | 3 | 3.0 |
*Major Histocompatibility Complex | 2 | 0.0 |
*Multigene Family | 2 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Hematopoiesis | 3 | 1.0 |
Intercellular Adhesion Molecule-1 | 6 | 2.0 |
Macrophages/*immunology | 3 | 1.0 |
Vascular Cell Adhesion Molecule-1 | 2 | 2.0 |
T-Lymphocytes/*physiology | 3 | 1.0 |
Hematopoietic Stem Cell Mobilization/*methods | 2 | 3.0 |
Antigens, CD3 | 2 | 0.0 |
Antigens, CD8 | 3 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Suspensions | 2 | 10.0 |
Lymphoma/immunology | 2 | 6.0 |
Dendritic Cells/*cytology/physiology/ultrastructure | 2 | 100.0 |
Skin/chemistry/*pathology/ultrastructure | 2 | 66.0 |
Antigens, CD36 | 5 | 3.0 |
Antigens, Surface/*metabolism | 2 | 3.0 |
Cell Adhesion Molecules/metabolism | 2 | 0.0 |
Xanthogranuloma, Juvenile/*pathology | 2 | 66.0 |
Histiocytosis, Langerhans-Cell/*diagnosis | 3 | 100.0 |
Antigens, CD1/biosynthesis/*metabolism | 3 | 100.0 |
Thymus Gland/*immunology | 3 | 5.0 |
Drug Resistance | 2 | 0.0 |
E-Selectin | 2 | 2.0 |
Antibodies/immunology | 2 | 0.0 |
Basement Membrane/immunology | 2 | 3.0 |
Langerhans Cells/cytology/*immunology/ultrastructure | 2 | 100.0 |
Keratinocytes/*immunology | 2 | 11.0 |
Neck | 2 | 3.0 |
Gingivitis/*pathology | 2 | 100.0 |
Cytoplasm/immunology | 2 | 2.0 |
Antigens, CD14 | 2 | 0.0 |
HLA-DR Antigens | 2 | 0.0 |
Dendritic Cells/*pathology/ultrastructure | 2 | 50.0 |
Antigen-Presenting Cells/immunology | 2 | 0.0 |
Dermatitis, Atopic/*immunology | 2 | 4.0 |
HLA Antigens/*immunology | 2 | 0.0 |
Histocompatibility Antigens Class I/*immunology | 2 | 1.0 |
Dendritic Cells/cytology | 2 | 16.0 |
Receptors, Antigen, T-Cell, gamma-delta | 2 | 3.0 |
Antigens, Differentiation/*analysis | 9 | 4.0 |
Autoradiography | 2 | 0.0 |
Histocytochemistry | 2 | 0.0 |
Antigens, CD/analysis/classification | 2 | 100.0 |
Antigens, Differentiation/*analysis/classification | 2 | 100.0 |
Immunoblotting | 2 | 0.0 |
Leukemia/*immunology | 2 | 5.0 |
Tumor Markers, Biological/*analysis/classification | 2 | 66.0 |
Leukemia, T-Cell, Acute/immunology | 2 | 16.0 |
Antigens, Surface/*immunology | 2 | 1.0 |
Microscopy, Phase-Contrast | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Antigens, Differentiation | 3 | 4.0 |
Antigens, Differentiation/*metabolism | 2 | 1.0 |
T-Lymphocytes | 2 | 0.0 |
Histocompatibility Antigens Class I/*genetics | 3 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/*analysis | 4 | 6.0 |
Antiretroviral Therapy, Highly Active | 2 | 0.0 |
United States | 3 | 0.0 |
Alleles | 2 | 0.0 |
*Genes, Structural | 2 | 0.0 |
HLA Antigens/*analysis | 2 | 0.0 |
Thymus Gland/cytology/embryology/*immunology | 2 | 50.0 |
Lectins, C-Type/metabolism | 4 | 26.0 |
Mannose-Binding Lectins/metabolism | 3 | 50.0 |
Dendritic Cells/*drug effects/physiology | 2 | 16.0 |
Interleukin-10/metabolism/secretion | 2 | 40.0 |
Interleukin-12/metabolism/secretion | 2 | 50.0 |
Phagocytosis/drug effects | 2 | 2.0 |
Isoenzymes/physiology | 2 | 4.0 |
Monocytes/cytology/immunology/metabolism | 2 | 14.0 |
Endocytosis/drug effects | 2 | 3.0 |
Protein Transport/immunology | 2 | 11.0 |
Antibodies | 2 | 0.0 |
Homeodomain Proteins/*genetics | 2 | 0.0 |
Incidence | 2 | 0.0 |
CD40 Ligand/pharmacology | 2 | 7.0 |
Endocytosis/drug effects/immunology | 2 | 100.0 |
